361 related articles for article (PubMed ID: 31556749)
1. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
Wang Y; De Clercq E; Li G
Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
[No Abstract] [Full Text] [Related]
2. Emerging reverse transcriptase inhibitors for HIV-1 infection.
Rai MA; Pannek S; Fichtenbaum CJ
Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
Jayaweera D; Dilanchian P
Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
[TBL] [Abstract][Full Text] [Related]
4. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
Dailly E; Allavena C; Deslandes G; Bouquie R; Jolliet P; Raffi F
Curr Clin Pharmacol; 2014; 9(4):399-403. PubMed ID: 24218996
[TBL] [Abstract][Full Text] [Related]
6. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Penazzato M; Giaquinto C
Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
[TBL] [Abstract][Full Text] [Related]
7. Etravirine for the treatment of HIV/AIDS.
Schrijvers R
Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
[TBL] [Abstract][Full Text] [Related]
8. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
10. [Role of etravirine in combination antiretroviral therapy].
Domingo P
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Zhang Z; Hamatake R; Hong Z
Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
[TBL] [Abstract][Full Text] [Related]
12. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Namasivayam V; Vanangamudi M; Kramer VG; Kurup S; Zhan P; Liu X; Kongsted J; Byrareddy SN
J Med Chem; 2019 May; 62(10):4851-4883. PubMed ID: 30516990
[TBL] [Abstract][Full Text] [Related]
13. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
de Béthune MP
Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
[TBL] [Abstract][Full Text] [Related]
14. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
15. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
Moyle G
Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
17. Rational Design of Doravirine: From Bench to Patients.
Hwang C; Lai MT; Hazuda D
ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
[TBL] [Abstract][Full Text] [Related]
18. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
19. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.
Usach I; Melis V; Peris JE
J Int AIDS Soc; 2013 Sep; 16(1):1-14. PubMed ID: 24008177
[TBL] [Abstract][Full Text] [Related]
20. Clinical uses of non-nucleoside reverse transcriptase inhibitors.
Harris M; Montaner JS
Rev Med Virol; 2000; 10(4):217-29. PubMed ID: 10891870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
